XRTX
NASDAQ · Pharmaceuticals
Xortx Therapeutics Inc
$0.91
-0.01 (-1.09%)
Financial Highlights (FY 2026)
Revenue
77.33M
Net Income
-7,315,175
Gross Margin
21.0%
Profit Margin
-2.6%
Rev Growth
-20.2%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 21.0% | 21.0% | 38.2% | 38.2% |
| Operating Margin | -0.3% | -0.2% | 27.9% | 25.3% |
| Profit Margin | -2.6% | -2.5% | 27.0% | 20.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 77.33M | 96.89M | 1.25M | 1.18M |
| Gross Profit | 16.25M | 20.36M | 479.3K | 450.1K |
| Operating Income | -208,794 | -235,452 | 350.1K | 298.2K |
| Net Income | -7,315,175 | -8,249,163 | 338.7K | 243.7K |
| Gross Margin | 21.0% | 21.0% | 38.2% | 38.2% |
| Operating Margin | -0.3% | -0.2% | 27.9% | 25.3% |
| Profit Margin | -2.6% | -2.5% | 27.0% | 20.7% |
| Rev Growth | -20.2% | -20.2% | +20.7% | +12.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 20.9K | 20.9K | 2.36M | 2.22M |
| Total Equity | 1.17M | 1.17M | 3.65M | 3.81M |
| D/E Ratio | 0.02 | 0.02 | 0.65 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -8,662,845 | -10,311,618 | 499.5K | 428.0K |
| Free Cash Flow | — | — | 161.5K | 118.2K |